Purpose. This study was aimed at investigating the occurrence and genetic mechanisms of resistance to ciprofloxacin, tetracycline and erythromycin in clinical isolates of Campylobacter jejuni recovered from human cases of acute gastroenteritis in Turkey.
INTRODUCTION
Campylobacter jejuni, a principal species of the genus Campylobacter, is one of the main causative agents of bacterial gastroenteritis worldwide. Both mammals and birds harbour a great number of C. jejuni cells in their digestive system [1, 2] . The transmission of this bacterium to humans occurs mainly through the consumption of raw or undercooked chicken meat, unpasteurised milk and dairy products, water and other food products cross-contaminated with raw chicken during food preparation in the kitchen. Campylobacter gastroenteritis is generally observed as an acute and self-limiting infection associated with symptoms of fever, abdominal cramps and watery/bloody diarrhoea that last only a few days [1, 2] . However, the young, the elderly and immunocompromised persons, in particular, can present with severe and prolonged cases that may be associated with bacteriaemia and extraintestinal infections [2, 3] . Such cases of campylobacteriosis require antibiotic treatment. The primary antibiotics preferred for the clinical treatment of campylobacteriosis cases are macrolides. Owing to their broad spectrum, fluoroquinolones have also found common use against enteric pathogens. Alternative antibiotics that can be used for therapy are tetracyclines and gentamycin. However, reports have drawn attention to an increased rate of resistance in Campylobacter isolates to these antibiotics that are commonly used for therapeutic purposes worldwide [4] . Fluoroquinolone resistance in C. jejuni is mostly due to the mutations in the quinolone resistance determining region (QRDR) of DNA gyrase A gene (gyrA) [5, 6] . Macrolide resistance is mostly chromosomal and arises from point mutations in the V domain of the 23S rRNA gene (e.g. A2074C and A2075G) [5, 6] . Furthermore, the presence of an rRNA methyltransferase gene, ermB, and single amino acid mutations in the L4/L22 ribosomal proteins have also been reported to confer macrolide resistance [7] . Tetracycline resistance is mainly mediated by the tetO gene, which is usually located on a plasmid but could also be found in the chromosome occasionally. tetO encodes a ribosomal protection protein and prevents the binding of tetracycline to the ribosome, thus leading to tetracycline resistance in C. jejuni [7, 8] .
In general, limited information is available on the prevalence and genetic mechanisms of antibacterial resistance in C. jejuni isolates recovered from human campylobacteriosis cases in Turkey, especially in comparison to the large amount of data on the subject from Europe and Northern America. Therefore, the purpose of this study was to investigate the occurrence and genetic mechanisms of resistance in human clinical C. jejuni isolates to clinically important antibiotics (i.e. erythromycin and ciprofloxacin, and to a lesser extent tetracycline) that are the drugs of choice for treatment of human Campylobacter infections when indicated.
METHODS
C. jejuni isolates C. jejuni isolates used in this study were obtained from the study of Kayman et al. [9] , where a total of 152 isolates of human origin were included. Characteristics of these isolates are as follows: they all were recovered from the stool samples of diarrheic patients with acute gastroenteritis cases at a Training and Research Hospital between March 2010 and March 2011 in Kayseri, Turkey. All of the isolates were identified to the species level by phenotypic and molecular tests. In addition, antimicrobial susceptibilities of the C. jejuni isolates to various antibiotics were determined by the disc diffusion method [9] .
Antimicrobial susceptibility testing
The MIC values of ciprofloxacin (CI), erythromycin (E), and tetracycline (TE) for C. jejuni isolates were determined with the epsilometer test (E-test). The E-test strips were purchased from Liofilchem s.r.l. (Roseto degli Abruzzi, Italy). In brief, bacterial suspensions were adjusted to 0.5 McFarland standard and inoculated onto solid MuellerHinton agar (MHA) (Merck, 1.05437, Germany) supplemented with 5 % of defibrinated sheep blood. E-test strips were placed onto plates inoculated and then plates were incubated under microaerobic conditions at 37 C for 48 h in an anaerobic chamber (Anaerocult C, Merck, Germany). Resistance to three or more antimicrobials was defined as multidrug resistance (MDR). The MIC values of the antibiotics were evaluated according to the recommendations of the Clinical and Laboratory Standard Institute (CLSI) [10] . Clinical breakpoints used for designation of isolates as susceptible (S), resistant (R) or intermediate (I) are given in Table 1 . In addition, epidemiologic cutoff (ECOFF) values set by of European Committee on Antimicrobial Susceptibility Testing (EUCAST) were used to determine the microbiological resistance to ciprofloxacin (>0.5), erythromycin (>4) and tetracycline (>2) in C. jejuni isolates [11] .
Extraction of genomic DNA A DNA extraction kit (Ultraclean DNA extraction kit, Mobio, USA) was used for the extraction of genomic DNA from the C. jejuni isolates. The extraction procedures were performed in accordance with the manufacturers' instructions. DNA extracts were stored at À20 C until they were used. The reference strain C. jejuni NCTC 11168 was used as a control.
Investigation of fluoroquinolone resistance
The presence of the most common point mutation causing fluoroquinolone resistance in Campylobacter, Thr-86-Ile (ACTfiATT), was investigated via a mismatch amplification mutation assay (MAMA) PCR using the primers CampyMAMAgyrA1 and CampyMAMAgyrA5 (Table 2) as described previously [12, 13] .
Investigation of macrolide resistance
A combined MAMA PCR assay, as described by Alonso et al. [14] , was used to determine the presence of two of the most common mutations (A2074C and A2075G) in the 23S rRNA gene conferring macrolide resistance. The mutation primers ERY2075-R and ERY2074-R (Table 2) , producing a band of 485 bp were used for detection of these specific mutations. In addition, primers 23S rRNA (Table 2) , producing a band of 697 bp, were used as the control for the target region.
Investigation of tetracycline resistance
The presence of tetracycline resistance gene, tetO, was investigated with a PCR assay as described by Gibreel et al. [15] using the primers DMT1 (TetOF) and DMT2 (TetOR).
The PCR-amplified products, which were resolved by 1 or 2 % agarose (Prona) gel electrophoresis (Thermo EC 330), were visualized with an ultraviolet (UV) transilluminator (VilberLourmat, Marne La Vallee, France). Table 2 shows the list of primers used and the expected amplicon size in this study.
Sequence analysis
The QRDR of the gyrA gene in C. jejuni isolates was amplified using the primers GZgyrA5 and GZgyrA6 (Table 2) and following the protocol as described by Zirnstein et al. [12] . For the confirmation of the MAMA PCR results and detection of other potential resistance conferring mutations, the QRDR region was sequenced using primers GZgyrA7 and GZgyrA8 (Table 2 ) in a total of 15 C. jejuni isolates (10 were resistant and five were susceptible to ciprofloxacin).
For the confirmation of the MAMA PCR results and detection for other potential macrolide resistance conferring mutations in the 23S RNA gene, sequencing was performed using primers 23SrRNA-F and 23SrRNA-R (Table 2 ) in a total of 14 C. jejuni isolates (nine were erythromycin resistant and five were erythromycin susceptible).
QIAquick PCR Purification Kit (Qiagen) was used to purify the amplified PCR products; Big Dye Direct Cycle Sequencing Kit (Applied Biosystems) was used for sequencing on an Applied Biosystems 3130 Genetic Analyser (Applied Biosystems) following the manufacturers' instructions. The sequences were analysed with CLC Main Workbench 6 (Qiagen-Bioinformatics, Aarhus C, Denmark), and compared to reference sequences available on the NCBI database (https://blast.ncbi.nlm.nih.gov/Blast.cgi) with the Nucleotide-Nucleotide Basic Local Alignment Search Tool (BLASTN).
RESULTS

MIC results
Of the 152 C. jejuni isolates tested in this study, 113 (74.3 %) were resistant to ciprofloxacin, 38 (25 %) were resistant to tetracycline and nine (5.9 %) were resistant to erythromycin based on CLSI breakpoints. The MIC values of the ciprofloxacin-resistant isolates were 8 µg ml À1 in 10 isolates, 12 µg ml À1 in 11 isolates, 16 µg ml À1 in six isolates, and 32 µg ml À1 in 86 isolates. Furthermore, 28 of the tetracycline-resistant isolates had an MIC value of 16 µg ml À1 , whilst 10 had an MIC value of 32 µg ml À1 . The MIC values of the erythromycin-resistant isolates were determined as 32 µg ml À1 in three isolates, 64 µg ml À1 in another three isolates, and 256 µg ml À1 in the remaining three isolates. The numbers of the antibiotic-resistant isolates detected and the MIC distributions are presented in Table 1 . The resistance rates based on ECOFF breakpoint criteria were similar to those of CLSI.
Multidrug resistance in the C. jejuni isolates In this study, C. jejuni isolates were also evaluated for multidrug resistance. Accordingly, only 3 (1.97 %) of the C. jejuni isolates were found to be resistant to three (ciprofloxacin, erythromycin and tetracycline) of the antibiotics tested.
Molecular mechanisms of resistance
All of the 152 C. jejuni isolates tested in this study produced a 673 bp band and were positive for the QRDR, as expected. However, only ciprofloxacin-resistant isolates (n=113) were ascertained to display a band at 265 bp with the MAMA PCR, indicating the presence of Thr-86-Ile mutation. All of the tetracycline-resistant isolates (n=38) produced a 559 bpband specific for the tetO gene. All of the erythromycinresistant isolates (n=9) produced a 485 bp-band by the MAMA PCR, indicating the presence of a macrolide resistance conferring specific mutation (either A2074C or A2075G). Overall, the results of the phenotypic susceptibility testing were found to be in accordance with the results obtained by the genetic testing (Table 3) .
Sequence analysis
Among the ciprofloxacin-resistant C. jejuni isolates based on the results of the phenotypic susceptibility testing and the presence of the resistance mutation (Thr-86-Ile) by the MAMA PCR, 10 were selected for further investigation for Grey shades indicate the resistant isolates for each antibiotic.
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the presence of resistance-conferring mutations in QRDR.
All of the 10 isolates were found to harbour the same mutation (Thr-86-Ile, ACAfiATA) as revealed by the MAMA PCR. On the other hand, none of the ciprofloxacin-susceptible isolates had any mutations in QRDR.
Furthermore, the 23S rRNA gene of nine C. jejuni isolates, which were erythromycin resistant by the phenotypic susceptibility testing and positive for the resistance mutations (either A2074C or A2075G) by the MAMA PCR, was sequenced. All of the nine isolates carried the point mutation A2075G, but none harboured the A2074C mutation (Table 3) . On the other hand, the erythromycin-susceptible isolates (n=5) were found to be negative for both of these mutations.
DISCUSSION
To the authors' knowledge, information available on the genetic analysis of antibacterial resistance in C. jejuni isolates recovered from human campylobacteriosis cases in Turkey is very scarce. The only study on this subject was conducted by Ongen and Nazik [16] for the investigation of the plasmid-mediated fluoroquinolone gene (qnr) in ciprofloxacin-resistant C. jejuni isolates (n=29). All isolates were found to be negative for this gene in that study.
Recent reports point to a significant increase in the resistance of C. jejuni to therapeutic antibiotics worldwide [6] . Of these antibiotics, the most important ones are considered to be fluoroquinolones and macrolides. Similar to the global trend, fluoroquinolone resistance in C. jejuni has also increased over time in Turkey. More specifically, the quinolone resistance rate was detected as 0 % in 1989 [17] [12] GZgyrA8 TAGAAGGTAAAACATCAGGTT 23SRNA-F TTAGCTAATGTTGCCCGTACCG For sequencing [14] 23SRNA-R AGCCAACCTTTGTAAGCCTCCG a certain extent, that the common use of enrofloxacin and sarafloxacin in veterinary medicine for treatment and prophylaxis purposes has had a significant influence over this increase in fluoroquinolone resistance in C. jejuni seen worldwide [23, 31, 45] .
The underlying molecular mechanism of fluoroquinolone resistance in C. jejuni mainly involves the mutation Thr-86-Ile in GyrA. Nonetheless, the mutations Asp90Asn, Thr86Lys, Thr86Ala, Thr86Val and Asp90Tyr are also involved in the resistance to fluoroquinolones [8, 46] . In the present study, the ciprofloxacin resistance rate of the C. jejuni isolates tested was determined as 74.3 % with the E-test, and molecular analysis (MAMA PCR) revealed all of the resistant isolates to be positive for a specific mutation (Thr-86-Ile) in the gyrA gene. The sequencing of QRDR in 10 of the resistant isolates for the detection of mutations in the gyrA demonstrated the presence of the same point mutation Thr-86-Ile (ACAfiATA) in all of the isolates. This finding is in agreement with many previous studies where this mutation was found to be the most predominant resistance-conferring mutation in C. jejuni [7, 12, 27, 36, 42] .
Research has shown that, in Turkey, a low level of microbial resistance has developed to erythromycin, which is considered as the most effective antibiotic for the treatment of campylobacteriosis. Indeed, erythromycin resistance was reported as 5. [7, 15, 44] . In the present study, the rate of macrolide resistance was determined as 5.9 %. This rate is in agreement with macrolide resistance prevalences previously reported from different locations in Turkey and from different countries mentioned above. On the other hand, high prevalence rates have also been reported for macrolide resistance [41, 49] and these high rates were attributed mostly to the particular geographical location and the widespread use of antibiotics. Furthermore, in some countries, the high resistance rates detected have been attributed to infections acquired by persons travelling abroad [28, 50] .
In the studies referred to above, erythromycin resistance was determined with a phenotypic susceptibility testing [9, 19-22, 24, 28, 36, 37, 39, 41, 44, 47, 48] , a molecular method [32, 42] or both of these methods [7, 14, 15, 27, 33, 49] . In fact, Gibreel et al. [51] reported that they detected point mutations in the 23S rRNA gene in eight out of the nine erythromycin-resistant C. jejuni isolates, and indicated that only one isolate did not carry any mutation. Furthermore, Lehtopolku et al. [49] reported a macrolide resistance rate of 43.42 % in 76 Campylobacter isolates. These researchers detected the point mutation A2075G in the 23S rRNA gene in 30 out of the 33 resistant isolates [49] . Similarly, all of the erythromycin-resistant isolates (n=9) in the current study were found to carry the same point mutation, which is also in accordance with many other studies reported worldwide, where the A2075G point mutation in the 23S rRNA gene was detected to be the predominant change in clinical and field C. jejuni isolates [6, 49, 51] . As expected, the erythromycin-susceptible isolates from the current study were found to be negative for both mutations.
Another antibiotic used to a lesser extent for the treatment of campylobacteriosis is tetracycline. While some researchers did not detect tetracycline resistance in Campylobacter in Turkey [19, 48] , there has been a significant increase in tetracycline resistance in [7, 15, 44] .
In the studies mentioned above, tetracycline resistance was determined with either a phenotypic susceptibility test alone [9, 22, 31, 33, 35, 39, 44] or by the use of both the phenotypic susceptibility test and a molecular method [7, 15, 27, 43, 52] . In the present study, 100 % of the tetracycline-resistant isolates carried the tetO gene in their genome (i.e. either chromosome or plasmid). Similarly, other researchers [27, 43] reported that all of the resistant isolates by a phenotypic testing had the tetO gene. Dasti et al. [52] reported that 54 % of the tetracycline-resistant isolates possessed the plasmid-mediated tetO gene. The specific location (chromosome or plasmid) of tetO in tetracycline-resistant isolates was not investigated in the current study. However, it is well known in tetracycline-resistant Campylobacter that tetO is commonly carried on a plasmid although it could occasionally be present in the chromosome [43, 52] .
The tetracycline resistance rate, which was detected as 25 % in the present study, shows that resistance to this particular antibiotic has progressively increased over time in Turkey. Nonetheless, the resistance rate detected in the present study is lower than those detected in some other countries [7, 31, 33, 35, 40, 41, 43, 44] . This difference could be attributed to the widespread use of antibiotics in animal production in these countries with higher resistance rates [33] .
The antibiotic susceptibility of the 152 C. jejuni isolates tested in the present study was previously performed using the disc diffusion method [9] . In that study, 113 (74.3 %) isolates were found to be ciprofloxacin-resistant, 38 (25 %) were tetracycline-resistant and nine (5.9 %) were erythromycin-resistant. The MIC values determined for these isolates in the present study using the E-test were found to be in total agreement with the previously obtained results. Therefore, owing to its low cost and ease of conduct, the disc diffusion method can readily be used to determine the susceptibility of C. jejuni to these antibiotics [53] .
Fluoroquinolone and tetracycline resistance have increased over the years in Turkey. On the other hand, no major change has occurred in the prevalence of erythromycin resistance since the 1980s. In addition, all of the antibioticresistant C. jejuni isolates based on the CLSI clinical breakpoint criteria were also found to be non-wild-type (i.e. microbiologically resistant) according to ECOFF criteria from EUCAST. Our results showed that the results of the phenotypic susceptibility testing were found to be in total agreement with the results of molecular analyses for all the antibiotics tested in the current study. Although the rate of tetracycline resistance is lower than the rate of fluoroquinolone resistance, the severe contraindications observed in the use of tetracycline in children prevents it from being a common treatment option in this age group. Furthermore, the low rate of resistance to erythromycin highly suggests that this particular antibiotic may be preferred as the first option for the treatment of C. jejuni infections when indicated in Turkey.
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